Therapy of Sialorrhea with Botulinum Neurotoxin
- PMID: 31542879
- PMCID: PMC6858891
- DOI: 10.1007/s40120-019-00155-6
Therapy of Sialorrhea with Botulinum Neurotoxin
Abstract
Botulinum neurotoxin (BoNT) is considered the treatment of choice for various symptoms and diseases such as focal dystonia and focal spasticity. The effects of BoNT on the salivary glands have also been known for years, but their use was limited because of a lack of approval studies. Now the indication of sialorrhea is approved in some countries for incobotulinumtoxinA, such as the USA and Europe, and therapy could also become the treatment of choice. According to the pivotal study, a dose of 100 units of incobotulinumtoxinA, which is divided into the parotid and submandibular glands, is recommended. RimabotulinumtoxinB is approved in the USA only. To define the value of this therapy, we must consider anatomy, physiology, and available therapies. Therapy includes conservative measures such as functional dysphagia therapy, oral or transdermal application of anticholinergics, and, in selected cases, radiotherapy and surgical procedures. A combination of different approaches is optional. On the basis of the evidence and clinical experience, BoNT injections will be the first line of pharmacotherapy for chronic sialorrhea.
Keywords: Anticholinergics; Botulinum toxin; Drooling; Dysphagia; Sialorrhea.
Conflict of interest statement
Wolfgang H. Jost is a consultant and/or speaker for the various BoNT manufacturers. Tobias Bäumer is a consultant and/or speaker for the various BoNT manufacturers. Rainer Laskawi is a consultant and/or speaker for the various BoNT manufacturers. Jaroslaw Slawek is a consultant and/or speaker for the various BoNT manufacturers. Armin Steffen is a consultant and/or speaker for the various BoNT manufacturers. Martin Winterholler is a consultant and/or speaker for the various BoNT manufacturers. Ganesh Bavikatte is a consultant and/or speaker for the various BoNT manufacturers. Björn Spittau has nothing to disclose.
Figures
Similar articles
-
[Therapy of Sialorrhea with Botulinum Toxin - An Update].Fortschr Neurol Psychiatr. 2022 May;90(5):222-232. doi: 10.1055/a-1802-3867. Epub 2022 Apr 22. Fortschr Neurol Psychiatr. 2022. PMID: 35453157 German.
-
[Therapy of sialorrhea with botulinum toxin].Fortschr Neurol Psychiatr. 2019 Oct;87(10):554-563. doi: 10.1055/a-0958-2417. Epub 2019 Jul 25. Fortschr Neurol Psychiatr. 2019. PMID: 31344747 German.
-
A critical review of incobotulinumtoxinA in the treatment of chronic sialorrhea in pediatric patients.Expert Rev Neurother. 2021 Oct;21(10):1059-1068. doi: 10.1080/14737175.2021.1979959. Epub 2021 Oct 4. Expert Rev Neurother. 2021. PMID: 34516331 Review.
-
Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeks.Parkinsonism Relat Disord. 2020 Jan;70:23-30. doi: 10.1016/j.parkreldis.2019.11.024. Epub 2019 Nov 26. Parkinsonism Relat Disord. 2020. PMID: 31794936 Clinical Trial.
-
Botulinum neurotoxin type A in the interdisciplinary treatment of sialorrhea in adults and children-update and practice recommendations.Front Neurol. 2023 Dec 13;14:1275807. doi: 10.3389/fneur.2023.1275807. eCollection 2023. Front Neurol. 2023. PMID: 38162447 Free PMC article. Review.
Cited by
-
Botulinum toxin in the treatment of sialorrhea in severe neurological patients with tracheotomy.Brain Behav. 2023 Aug;13(8):e3164. doi: 10.1002/brb3.3164. Epub 2023 Jul 17. Brain Behav. 2023. PMID: 37461166 Free PMC article.
-
The effectiveness of ultrasound-guided injection of BTX-A in the management of sialorrhea in neurogenic dysphagia patients.Laryngoscope Investig Otolaryngol. 2023 Oct 9;8(6):1607-1615. doi: 10.1002/lio2.1164. eCollection 2023 Dec. Laryngoscope Investig Otolaryngol. 2023. PMID: 38130251 Free PMC article.
-
Guidelines for the Use of Botulinum Toxin in Otolaryngology From the Korean Society of Laryngology, Phoniatrics and Logopedics Guideline Task Force.Clin Exp Otorhinolaryngol. 2023 Nov;16(4):291-307. doi: 10.21053/ceo.2023.00458. Epub 2023 Oct 25. Clin Exp Otorhinolaryngol. 2023. PMID: 37905325 Free PMC article.
-
Oral health effects of botulinum toxin treatment for drooling: a systematic review.Med Oral Patol Oral Cir Bucal. 2021 Mar 1;26(2):e172-e180. doi: 10.4317/medoral.24101. Med Oral Patol Oral Cir Bucal. 2021. PMID: 33340083 Free PMC article.
-
Recent Developments in Engineering Non-Paralytic Botulinum Molecules for Therapeutic Applications.Toxins (Basel). 2024 Apr 3;16(4):175. doi: 10.3390/toxins16040175. Toxins (Basel). 2024. PMID: 38668600 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources